The study was aimed to evaluate the efficacy of extra virgin olive oil (EVOO) supplementation compared to placebo to prevent HFS by observing changes in serum COX 2, malondialdehyde (MDA), and TNF α levels in breast cancer and colorectal cancer patients undergoing capecitabine chemotherapy. Current study was designed as a single-center prospective randomized clinical trial. The patients were Stage III or Stage IV colorectal and breast cancer patients receiving capecitabine-based chemotherapy who enrolled in the trial voluntarily. All patients were divided randomly into three groups treated with EVOO, olive oil, or placebo. The incidence of hand foot syndrome was documented. The serum COX 2, malondialdehyde (MDA), and TNF α levels before and after chemotherapy was documented.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Hand Foot Syndrome
Timeframe: 3 cycle of chemotherapy (63 days)
Serum COX-2 Concentration
Timeframe: 3 cycle of chemotherapy (63 days)
Serum malondialdehyde concentration
Timeframe: 3 cycle of chemotherapy (63 days)
Serum Tumor Necrosis Factor Alpha Concentration
Timeframe: 3 cycle of chemotherapy (63 days)